Roger E. Susi - 18 Dec 2023 Form 4 Insider Report for IRADIMED CORP (IRMD)

Source evidence 5 source fields
Form type
4
Accepted by SEC
20 Dec 2023, 16:05:10 UTC
Previous filing
13 Dec 2023
Next filing
22 Dec 2023
SEC filing
View on sec.gov
Reporting owner 1 detail
Reporting owner signature
/s/ Roger E. Susi

Key filing fact

Roger E. Susi filed Form 4 for IRADIMED CORP (IRMD) on 20 Dec 2023.

Key facts

  • This page summarizes Roger E. Susi's Form 4 filing for IRADIMED CORP (IRMD).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 20 Dec 2023, 16:05.

Change

  • Previous filing in this sequence was filed on 13 Dec 2023.
  • Current net transaction value: -$446,099.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRMD transaction

Common Stock

Sale

Transaction value
$220,402
Shares
-5,000
Change %
-2.7%
Price
$44.08
Shares after
177,950
Date
18 Dec 2023
Ownership
By Roger E. Susi Revocable Trust
Footnotes
F1, F2
IRMD transaction

Common Stock

Sale

Transaction value
$225,696
Shares
-5,000
Change %
-2.8%
Price
$45.14
Shares after
172,950
Date
19 Dec 2023
Ownership
By Roger E. Susi Revocable Trust
Footnotes
F1, F3
IRMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,362,500
Date
18 Dec 2023
Ownership
By Matthew Susi 2008 Dynasty Trust
Footnotes
F4
IRMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,362,500
Date
18 Dec 2023
Ownership
By Phillip Susi 2008 Dynasty Trust
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2023.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $43.33 to $45.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $43.80 to $45.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .